Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.
The Federal Circuit's October 2008 decision in In re Bilski, 545 F.3d 943 (Fed. Cir. 2008) (en banc), created uncertain implications for biotechnology regarding the applicable standard for patent eligibility under 35 U.S.C. '101. In its recent one-paragraph opinion in Classen Immunotherapies v. Biogen IDEC, 2008 WL 5273107 (Fed. Cir. 2008), the Federal Circuit left many issues unexplained, but it did make one thing clear: The Bilski standard, now being applied in the area of biomedical technology, poses a significant threat to the viability of patents claiming diagnostic methods.
The Bilski Case
The DOJ's Criminal Division issued three declinations since the issuance of the revised CEP a year ago. Review of these cases gives insight into DOJ's implementation of the new policy in practice.
The parameters set forth in the DOJ's memorandum have implications not only for the government's evaluation of compliance programs in the context of criminal charging decisions, but also for how defense counsel structure their conference-room advocacy seeking declinations or lesser sanctions in both criminal and civil investigations.
This article discusses the practical and policy reasons for the use of DPAs and NPAs in white-collar criminal investigations, and considers the NDAA's new reporting provision and its relationship with other efforts to enhance transparency in DOJ decision-making.
Active reading comprises many daily tasks lawyers engage in, including highlighting, annotating, note taking, comparing and searching texts. It demands more than flipping or turning pages.
There is no efficient market for the sale of bankruptcy assets. Inefficient markets yield a transactional drag, potentially dampening the ability of debtors and trustees to maximize value for creditors. This article identifies ways in which investors may more easily discover bankruptcy asset sales.